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any bacterial and viral pathogens exploit carbohydratebinding proteins (lectins) as part of their infection cycle. This includes viral glycans binding to host cells, 1 bacterial lectins modulating biofilm formation 2 or cell adhesion, 3, 4 or secreted toxins which are glycan-binding in their mode of action. 5 With the increase in antimicrobial resistance 6 there is an urgent need for new therapeutics and diagnostics which are not based on the traditional smallmolecule approach. Glycans typically have weak affinities to lectins (carbohydrate binding proteins which are not enzymes nor antibodies) in mM range. In contrast, due to the cluster glycoside effect, multivalent presentation of glycans on, e.g., polymers, particles, or surfaces gives a nonlinear increase in affinity, such that sub nM affinities can be obtained. 7−10 Hence there are significant opportunities in the design of multivalent glycomaterials as prophylactic treatments and biosensors and for understanding the glycome. 4,11−17 The cholera toxin (CTx) is a lectin produced as a virulence agent by Vibrio cholerae and binds via its adhesive subunit (CTxB) to the GM-1 glycan on the surface of human gut epithelial cells, with more than 1 million cases/year globally. 18 Galactosylated multivalent systems have been studied as decoys for CTxB, using polymers, 19−21 dendrimers, 22 protein scaffolds, 23 and a picomolar-active pentavalent calix [5] arene. 24 These examples are all homogeneous materials bearing a single glycan/functionality, but Worstell et al. found that CTxB binding to GM-1 surfaces is enhanced by the addition of fucose, which was not thought to have affinity for CTxB. 25 Dimeric fucose has also been shown to competitively inhibit CTxB binding to epithelial cells. 26 While there is significant evidence for high affinity binders to CTxB (and other lectins) selectivity still remains a challenge; most lectins have offspecific affinity for other glycans, and any glycan can bind several lectins, especially for monosaccharides which lack a complex 3-D structure required for a match. 27 Richards et al. and Kiick et al. have demonstrated that modulation of the galactose-backbone linker length enabled modulation of the relative affinity of galactose polymers to CTx, based on accessibility of the ligands into the deep binding pocket of CTx. 19, 21 Bundle and co-workers have developed galactosylated multivalent scaffolds with increased affinity by introduction of additional functionality to target the allosteric N-acyl-neuraminic acid binding site in CTxB 28 with aromatic residues found to enhance affinity. 20 Fieschi and co-workers have developed small-molecule and low valency compounds to selectively target DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin) without crossbinding to the Langerin lectin, which is essential for HIV antiadhesives. 29, 30 Hartman and co-workers and Percec and coworkers have demonstrated that heterogeneous glycopolymers (with more than one glycan) can show surprising increases in affinity due to a combination of spacing and steric blocking effects. 31−33 In short, a homoglycopolymer may not always be the most avid binder, nor the most potent inhibitor, and hence exploring more chemical space using heterogeneous glycopolymers may enable selectivity to be introduced.
Advances in controlled reversible-deactivation radical polymerization and bio-orthogonal 34 (click) reactions enable easy access to a wide range of architectures and hence opportunities to modulate affinity. Becer et al. have shown that changing from flexible to rigid 35 or linear to star shapes has profound effects on glycopolymer binding of DC-SIGN and dendritic cell cytokine production. 36, 37 The introduction of selectivity toward relevant lectins is essential to enable translation of these exciting materials.
We report here the synthesis and lectin binding properties of glycopolymers obtained using thiolactone chemistry. 38−40 This functional group enables one-pot, two-sequence reactions on a single monomer unit, to allow the linker chemistry in proximity to the primary binding unit (galactose) to be modulated. Using a combination of inhibitory assays and biolayer interferometry we demonstrate that the selectivity and affinity of glycopolymers can be tuned through introduction of secondary functionalities and show that the total binding capacity, not affinity, correlates strongly with inhibitory activity.
To introduce variable carbohydrate density on polymer backbones, the reactive precursor, thiolactone acrylamide (TLAm), was copolymerized with N-hydroxyethylacrylamide (HEA) using RAFT (reversible addition−fragmentation chaintransfer) polymerization ( Figure 1 ). The molar ratio of TLAm was varied from 5 to 20% to ensure a soluble polymer was obtained but with sufficient valency for cluster glycoside enhancement. 8, 19, 41 All polymers were analyzed by SEC, 1 H NMR, and FTIR analysis ( Table 1) .
The reactive thiolactone precursor polymers were glycosylated in a one-pot, two-stage process. 38 Thiolactones were first ring-opened by addition of benzylamine or glucosamine (secondary binding units), releasing the thiol group which could then react with β-1-O-allyl galactose tetra-acetate (primary binding unit; Supporting Information for synthesis) by "thiol−ene" radical click chemistry. 42 The acetate groups were quantitatively removed by sodium methoxide, followed by dialysis, and confirmed by FTIR spectroscopy. By using this strategy, a panel of doubly modified glycopolymers intended to mimic GM-1 was established. The number of galactose/chain is in Table 1 . A longer, hexyl, linked galactose was also synthesized and used (see below for discussion).
With this diverse panel of variable carbohydrate density and secondary units glycopolymers in hand, their potency to inhibit the binding of CTxB and RCA 120 (Ricinus communis agglutinin which also has affinity for terminal galactose 43 ) was evaluated by a fluorescence-linked sorbent assay. 19 Fluorescently labeled lectins were incubated with a serial dilution of each polymer and then tested for binding to a galactose-modified microtiter plate. Less fluorescence indicated more inhibition. 
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Letter expected. Against RCA 120 (which has a surface-accessible, relatively unhindered, galactose binding site) there was little impact of changing the secondary unit from glucose to benzyl with MIC 50 < 0.1 mg mL −1 observed. In dramatic contrast, the benzyl-modified glycopolymers were very poor inhibitors of CTxB binding, with essentially no inhibition (which does not necessarily rule out binding; see below). The glucose-modified polymer was a potent inhibitor with μM MIC 50 values in terms of [Galactose] , which is nM in [polymer] (due to their relatively high molecular weight). The lower density polymers (5%) were more potent inhibitors than higher density ones (20%) on a per-galactose basis. Nonlinear relationships between galactose density and CTX inhibition have previously been reported on both rigid 21 and flexible glycopolymers, 19 and one of the most potent inhibitors reported had only five galactose units but perfect symmetry matching with CTxB. 23 Per-sugar affinity gains are obtained by matching the spacing between binding pockets and controlling accessibility as is seen here. The lack of inhibitory activity for the benzyl modification was surprising, as introducing aromatic groups near galactose to target an allosteric site in CTxB has proven beneficial. 20, 28 However, this requires precision placement of individual ligands which might not occur here, and the benzyl unit could simply be acting as a steric block. A simple docking study was conducted using the "Swissdock" server to probe if the repeat unit could access the CTx binding pocket. This suggested that the linker could extend sufficiently deep into the pocket (12.7 Å) but would be subject to significant steric requirements if on a polymer backbone and did not show any favorable interactions. To probe the interactions in more detail, biolayer interferometry (BLI) was employed. BLI enables label-free evaluation of binding interactions and is similar to surface plasmon resonance (SPR). 44 Lectins were immobilized onto the BLI sensors using conventional NHS/ EDC coupling. The polymers were studied in a dosedependent manner against the lectins, and results were fitted using a heterogeneous sites model (Figure 3) . Figure 3A and B shows example BLI binding curves for glucose and benzyl secondary substituents. In both cases there are clear association and dissociation phases, and dosedependent responses in total mass bound are observed. The glucose-modified polymers showed a steeper association phase and overall larger Δ max (mass bound). Figure 3C shows the total mass captured (Δ max ) by the surface-immobilized CTxB per polymer. For all galactose densities, polymers with glucose as the secondary unit showed significantly increased binding compared to the benzyl. Our postpolymerization synthetic strategy ensures these differences are not biased by M w differences and hence are due to the ability of the polymers to bind to the CTxB. Interestingly, the Δ max values correlated with the MIC 50 values (Figure 2) , suggesting that the total extent of binding is the most important descriptor of inhibitory potency rather than just affinity, along with the ability to bind multiple sites simultaneously. 45, 46 Drug residence time, rather than affinity, has emerged as a key target in small-molecule drug discovery, supporting this design approach. 47 Estimates of the dissociation constant were made from the fitted BLI curves (to a heterogeneous site model) which suggests that the glucose polymers had lower overall affinity, but this is biased by the plateauing effect at low concentrations and low mass captured, so is only an estimate. Extracted values are tabulated for completeness in the Supporting Information but due to the heterogeneity and incomplete fitting were not considered further. To reiterate, the aim here was to develop inhibitors, and the BLI enabled a link to the observed MIC testing.
Analysis of the CTxB binding site depth showed that the allyl linker was only just long enough to probe into it, which might explain the observations above. Therefore, a longer linker, β-D-1-O-hexyl-galactose tetra-acetate, was synthesized and incorporated into the same precursor polymers, with both benzyl and glucose secondary groups to give a linker that can probe up to 16.5 Å, rather than 12.7 Å. BLI was again conducted, and the total mass captured is plotted in Figure 4 . This increase in linker length did not modulate the total mass captured significantly, with the same trends seen as for the allyl linker, suggesting both had equal access. This suggests the secondary units are modulating the overall sterics, rather than binding to any defined allosteric sites (as the change in spacing would change this). These inhibitory assays and BLI results 
Letter together demonstrate that by using accessible and modular chemistries the affinity and selectivity of multivalent glycopolymer antiadhesives can be tuned by proximal modification of the key binding motifs, in addition to the well-explored impact of polymer molecular weight and branching.
In conclusion, we have taken advantage of the modular and versatile thiolactone functionality to develop more complex glycopolymers bearing both primary glycan ligands and also secondary units to modulate the selectivity of these materials toward lectins implicated in disease. A library of polymers were synthesized with systematic variation of their glycan density and secondary group, and these were evaluated in a competitive binding assay. This analysis revealed that low density glycopolymers were the most active (lowest MIC 50 ). Furthermore, addition of secondary groups proximal to the galactose enabled complete switching off of the activity versus the cholera toxin, while retaining all activity against RCA 120 , and is a rare example of a glycopolymer with selectivity. Biolayer interferometry revealed that the total mass of glycopolymers bound by the lectin correlated strongly with the observed inhibitory activity which will help the design of new inhibitors for application in biosensing or antiadhesion therapy.
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